Form 4: Artivion SVP Exercises Options, Sells Shares

Artivion's SVP of Clinical & MD Affairs, Marshall S. Stanton, exercised stock options and subsequently sold an equivalent number of common shares in pre-planned transactions.

Summary

• Marshall S. Stanton, SVP, Clinical & MD Affair at Artivion, Inc. (AORT), reported transactions on November 21, 2025.
• Stanton acquired a total of 47,376 shares of common stock through the exercise of stock options.
• 20,301 shares were acquired at an exercise price of $18.44 per share.
• 27,075 shares were acquired at an exercise price of $11.03 per share.
• Concurrently, Stanton disposed of a total of 47,376 shares of common stock through sales.
• Sales occurred at weighted average prices ranging from $44.91 to $45.346 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Stanton's direct beneficial ownership of common stock is 44,753 shares.

Sentiment

Score: 6

Explanation: The transactions represent a routine exercise of stock options and subsequent sale of shares by a senior executive, likely for personal financial planning, as indicated by the Rule 10b5-1 plan. The significant profit realized from the option exercise is a positive for the executive, but the net reduction in direct ownership could be viewed neutrally by the market.

Positives

• The exercise of stock options indicates a realization of value from previously granted equity incentives.
• The exercise prices ($18.44 and $11.03) are significantly lower than the sale prices (around $44-$45), indicating a substantial profit for the insider.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting a pre-planned liquidity event rather than a reaction to immediate company news.

Negatives

• The sale of 47,376 shares by a Senior Vice President reduces their direct equity stake in the company, which could be interpreted as a slight reduction in insider conviction, although it's offset by the option exercise.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider selling neutrally given the 10b5-1 plan, but some might interpret it as a slight reduction in insider confidence. The overall impact is likely minimal as it's a common compensation management activity.

Key Dates

Recommendation

This Form 4 filing details a pre-planned exercise of stock options and subsequent sale of shares by a senior executive. Such transactions are common for managing equity compensation and personal liquidity and do not typically signal a change in the company's fundamental outlook or operational performance. The transactions were executed under a Rule 10b5-1 plan, further indicating a lack of immediate market timing intent. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' position, assuming the investor's existing thesis on Artivion remains intact.

Keywords

Artivion, AORT, Insider Trading, Form 4, Stock Options, Share Sale, Marshall S. Stanton, Equity Compensation, Rule 10b5-1